Articles

  • 1 week ago | rarediseaseadvisor.com | Ed Tobias

    The times they may be ‘a-changin’ when it comes to treating older people with multiple sclerosis—people like me. For years it’s seemed as if many neurologists were being guided by a 2017 review by University of British Columbia researchers reporting that disease activity declines as people with MS grow older.

  • 1 month ago | rarediseaseadvisor.com | Ed Tobias

    Change can be good. For months, I’d been bothered by leg pain, which I’d chalked up as just my multiple sclerosis (MS) doing its thing. Sometimes it was an ache in one hip. Or the other. Or both. Sometimes it was a sharp pain, shooting from my left hip and traveling down into my thigh via what I assumed to be my sciatic nerve. My glutes always ached. Recently, lying in bed at night, I’d had very painful cramps along my left shin, extending down to the top of my foot.

  • 1 month ago | rarediseaseadvisor.com | Ed Tobias

    I like to play games. The Words With Friends app and online puzzles, like Connections on the New York Times app, keep me thinking. Online games can be important to someone with multiple sclerosis (MS), where cognitive fog and fatigue are both common symptoms. So I was very interested when I was offered the chance to try a website and app called BrainHQ. It’s designed to help improve the brain’s processing speed and, by doing that, help improve things like cognition and fatigue.

  • 1 month ago | rarediseaseadvisor.com | Ed Tobias

    The headline on the news release that dropped into my inbox recently read: “FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs.”Take animals out of the drug approval process? Really? Monocolonal antibody therapies are some of the highest efficacy treatments in the multiple sclerosis (MS) arsenal. They include natalizumab (Tysabri), alemtuzumab (Lemtrada), ocrelizumab (Ocrevus), ofatumumab (Kesimpta), and ublituximab (Briumvi).

  • 2 months ago | rarediseaseadvisor.com | Ed Tobias

    Have you ever looked at a research paper and thought, “Why in the world did they waste time and money on that?” I saw one of those reports the other day about multiple sclerosis (MS) fatigue and life quality. The news was headlined “Fatigue significantly contributes to impaired well-being in MS.”The Finnish researchers studied data from more than 500 patients with MS.